Dr Spratt on Uncertainties Regarding Treatment Intensification in High-Risk Prostate Cancer

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.

Related Keywords

Daniel Spratt ,School Of Medicine ,Department Of Radiation Oncology ,Case Comprehensive Cancer Center ,Case Western Reserve University ,Developmental Therapeutics Program ,Radiation Oncology ,Prostate Cancer ,Treatment Intensification ,High Risk ,Abiraterone ,Adt ,Enzalutamide ,Enzarad ,Atlas ,Stampede ,